Mammography Screening Consensus for Average-Risk Women
For average-risk women, begin biennial screening mammography at age 40 and continue through at least age 74, with the option to screen annually based on individual preference.
Age to Begin Screening
The most recent and authoritative guidance comes from the 2024 USPSTF recommendation, which now recommends biennial screening starting at age 40 1. This represents a significant shift from their previous 2016 guidance and aligns more closely with other major organizations.
Key Age-Based Recommendations:
Ages 40-44:
- USPSTF (2024): Biennial screening recommended 1
- ACS (2015): Optional annual screening based on patient preference 2
- ACR: Annual screening recommended 3
- NCCN: Annual screening recommended 3
Ages 45-54:
- ACS: Annual screening (strong recommendation for starting at 45) 2
- USPSTF: Biennial screening 1
- ACR/NCCN: Annual screening 3
Ages 55-74:
- ACS: Transition to biennial or continue annual 2
- USPSTF: Biennial screening 1
- ACR/NCCN: Continue annual 3
Age 75 and older:
- Continue screening if good health and life expectancy ≥10 years 3, 2
- USPSTF: Insufficient evidence to assess benefits/harms 3, 1
- Age alone should never be the sole reason to discontinue screening 3
Screening Interval: Annual vs. Biennial
There is notable divergence here:
- USPSTF recommends biennial (every 2 years) for all ages 40-74 1
- ACR and NCCN recommend annual screening starting at age 40 3, 4
- ACS recommends annual until age 55, then biennial or annual based on preference 2
The rationale for annual screening centers on maximizing mortality reduction and detecting interval cancers that emerge between biennial screens. The biennial approach emphasizes reducing false positives and overdiagnosis while maintaining substantial mortality benefit.
Screening Modality
Mammography (digital or digital breast tomosynthesis/DBT) is the only recommended primary screening modality for average-risk women 3, 1, 5, 6.
What NOT to Use for Routine Screening:
- Clinical breast examination: NOT recommended by ACS 2 and CTFPHC 3
- Breast self-examination: NOT recommended 3
- MRI, ultrasound, or DBT as adjunctive screening in dense breasts: Insufficient evidence 3, 1
The CTFPHC explicitly recommends against MRI, tomosynthesis, or ultrasound for average-risk women (strong recommendation) 3.
Special Considerations
Dense Breasts:
- Supplemental screening with ultrasound or MRI has insufficient evidence to recommend for or against 3, 1
- ACR suggests ultrasound may be considered, but balance increased detection against increased false positives 3
Patient Navigation Services:
The 2025 WPSI recommendation emphasizes providing patient navigation services to ensure complete follow-up after abnormal mammograms, as gaps in insurance coverage often lead to incomplete diagnostic workup 7. This addresses a critical equity issue.
Critical Pitfalls to Avoid
Don't stop screening based solely on age 75 - assess health status and life expectancy instead 3, 2
Don't recommend clinical breast exams or self-exams as screening tools - no mortality benefit and potential for harm from false positives 3, 2
Don't order supplemental screening (ultrasound/MRI) for dense breasts in average-risk women - insufficient evidence of net benefit 3, 1
Don't delay starting screening until age 50 - the 2024 USPSTF update specifically moved the starting age down to 40 1
Practical Algorithm
For average-risk women presenting for screening guidance:
Age 40-74: Offer biennial mammography (USPSTF standard) 1, with option to screen annually if patient values more frequent screening and accepts higher false-positive rate
Age 75+: Continue screening if:
- Good overall health status
- Life expectancy ≥10 years
- Patient desires continued screening
Dense breasts on mammogram: Continue routine mammography; do not routinely add supplemental imaging
Abnormal screening result: Ensure patient navigation services are available to complete diagnostic workup 7
Evidence Quality Note
The 2024 USPSTF guideline 1 represents the most recent high-quality evidence synthesis and carries a Grade B recommendation (moderate certainty of moderate net benefit) for biennial screening ages 40-74. This supersedes older recommendations and reflects updated modeling studies showing benefit of earlier screening initiation, particularly for Black women who have higher mortality rates from breast cancer.